Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 4 2

Status

Unknown 2Completed 2Terminated 1

Sponsor Class

OTHER 2INDUSTRY 2NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5Thoracic 1Genitourinary 1CNS 1

Conditions

Stomach Neoplasms 2Rectal Neoplasms 1Osteoarthritis 1Colorectal Neoplasms 1Colonic Neoplasms 1Cancer Pain 1Barrett Esophagus 1Adenomatous Polyposis Coli 1

Interventions

Oxaliplatin 1409Fluorouracil 1298Capecitabine 1085Gemcitabine 1042Leucovorin 928Irinotecan 815Bevacizumab 803Cisplatin 666Radiotherapy 535Cetuximab 469pembrolizumab 428Paclitaxel 389Nivolumab 336130-nm albumin-bound paclitaxel 322Drug Therapy 314Docetaxel 286S 1 (combination) 273Sorafenib 266Folfox protocol 261Albumin-Bound Paclitaxel 259sintilimab 211durvalumab 209Surgical Procedures, Operative 203tislelizumab 202Radiosurgery 202lenvatinib 201apatinib 198Carboplatin 186Magnetic Resonance Spectroscopy 181regorafenib 180

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × rofecoxib × Gastrointestinal × Clear all
NCT00140894 2019-09-20

A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) (0966-205)(TERMINATED)

Merck Sharp & Dohme LLC

Phase 4 Terminated
62 enrolled
Gastrointestinal

Cancer Pain, Osteoarthritis, Adenomatous Polyposis Coli

NCT00031863 2013-08-02

Rofecoxib After Surgery in Treating Patients With Stage II or Stage III Colorectal Cancer

National Cancer Institute (NCI)

Phase 3 Completed
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00637988 2011-01-21

Barrett's Esophagus - 315 - 3 Way Cross Over

AstraZeneca

Phase 4 Completed
32 enrolled
Gastrointestinal

Barrett Esophagus

NCT00165048 2005-12-09

Selective COX-II Inhibitor as a Palliative Therapy in Patients With R1 or R2 Resection for Disseminated Stomach Cancer - A Multi-Centre Prospective Randomized Controlled Trial

Chinese University of Hong Kong

Phase 3 Unknown
206 enrolled
Gastrointestinal

Stomach Neoplasms

NCT00164892 2005-11-17

Selective COX-II Inhibitor as an Adjuvant Therapy in Patients With Resectable Advanced Stomach Cancer ( Histological Staging ≥ T2N1) - A Multi-Centre Prospective Randomised Controlled Trial

Chinese University of Hong Kong

Phase 3 Unknown
214 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡